drugset / Trial / NCT00702962
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Phase 1/2
Terminated
8 enrolled
Milton S. Hershey Medical Center
Merck Sharp & Dohme LLC · collabUniversity of Pennsylvania · collab
SequentialOpen-labelTreatment
Summary
The Phase I portion of the study is to assess the maximum tolerated dose of vorinostat when combined with carboplatin plus etoposide. The Phase II portion is to determine progression-free survival among patients with extensive disease small cell lung cancer receiving carboplatin plus etoposide with vorinostat.
Timeline
- Start
- 2008-09
- Primary completion
- 2012-07
- Completion
- 2012-07
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 200 mg | Oral |
| Subject | Vorinostat | Small molecule | 300 mg | Oral |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |